Efficacy and safety of sublingual immunotherapy in children

Expert Review of Clinical Immunology

Volumn 12, Issue 1, 2016, Pages 49-56

  Arasi, Stefania ^a   Passalacqua, Giovanni ^b   Caminiti, Lucia ^a   Crisafulli, Giuseppe ^a   Fiamingo, Chiara ^a   Pajno, Giovanni Battista ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

allergen specific immunotherapy; efficacy of SLIT; safety of SLIT; sublingual immunotherapy (SLIT)

Indexed keywords

ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; BRONCHUS HYPERREACTIVITY; CHILD; CLINICAL EFFECTIVENESS; FOOD ALLERGY; HUMAN; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT ALLERGY; REVIEW; RISK REDUCTION; SENSITIZATION; SUBLINGUAL ALLERGEN IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; DESENSITIZATION; EUROPE; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; SUBLINGUAL DRUG ADMINISTRATION; UNITED STATES;

IMMUNOGLOBULIN E;

ADMINISTRATION, SUBLINGUAL; CHILD; DESENSITIZATION, IMMUNOLOGIC; EUROPE; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; UNITED STATES;

EID: 84949085943     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2016.1102058     Document Type: Review

References (72)

1. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997;99:450-453.
2. Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E, et al. Local immunotherapy. Allergy. 1998;53:933-944.
3. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7:6.
4. Passalacqua G, Canonica GW. Sublingual immunotherapy: focus on tablets. Ann Allergy Asthma Immunol. 2015;115:4-9.
5. Calderón MA, Casale TB, Togias A, et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011;127:30-38.
6. Hoeks SB, De Groot H, Hoekstra MO. Sublingual immunotherapy in children with asthma or rhinoconjunctivitis: not enough evidence because of poor quality of the studies; a systematic review of literature. Ned Tijdschr Geneeskd. 2008;152:261-268.
7. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol. 2013;132:1322-1336.
8. Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol. 2011;127:64-71, 71, e61-64.
9. Stelmach I, Kaluzinska-Parzyszek I, Jerzynska J, et al. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy. 2012;67:312-320.
10. Yonekura S, Okamoto Y, Sakurai D, et al. Sublingual immunotherapy with house dust extract for house dust-mite allergic rhinitis in children. Allergol Int. 2010;59:381-388.
11. Ahmadiafshar A, Maarefvand M, Taymourzade B, et al. Efficacy of sublingual swallow immunotherapy in children with rye grass pollen allergic rhinitis: a double-blind placebo-controlled study. Iran J Allergy Asthma Immunol. 2012;11:175-181.
12. Wahn U, Klimek L, Ploszczuk A, et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. J Allergy Clin Immunol. 2012;130:886-893. e885.
13. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006;97:141-148.
14. Roeder E, Berger MY, de Groot H, et al. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol. 2008;19:197-207.
15. Compalati E, Penagos M, Tarantini F, et al. Specific Immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunology. 2009;102:22-28.
16. Larenas-Linnemann D. Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Curr Opin Allergy Clin Immunol. 2009;9:168-176.
17. Halken S, Agertoft L, Seidenberg J, et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol. 2010;21:970-976.
18. Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis [published online June 29, 2015]. JAMA Intern Med.
19. Demoly P, Calderon MA, Casale TB, et al. The value of pre-and co-seasonal sublingual immunotherapy in polleninduced allergic rhinoconjunctivitis. Clin Transl Allergy. 2015;5:18.
20. Miceli Sopo S, Macchiaiolo M, Zorzi G, et al. Sublingual immunotherapy in asthma rhinitis and rhinoconjunctivitis; systematic review of paediatric literature. Arch Dis Childhood. 2004;89:620-624.
21. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005;15:9-16.
22. Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133:599-609.
23. Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy. 2010;40:922-932.
24. Stelmach I, Kaczmarek-Wozniak J, Majak P, et al. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy. 2009;39:401-408.
25. Laynaert B, Neukirch C, Kony S, et al. Association between asthma and rhinitis according to atopic sensitization in a population based study. J Allergy Clin Immunol. 2004;113:86-93.
26. Guerra S, Sherrill DL, Baldacci S, et al. Rhinitis is an independent factor for developing cough apart from colds among adults. Allergy. 2005;60:343-349.
27. Shaabban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal-population based study. Lancet. 2008;372:1049-1057.
28. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160.
29. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with Allergic rhino conjunctivitis. J Allergy Clin Immunol. 2004;114:851-857.
30. Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol. 2008;101:206-211.
31. Walker SM, Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized controlled trial. J Allergy Clin Immunol. 2001;107:87-93.
32. Pajno GB, Passalacqua G, Vita D, et al. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietariainduced respiratory allergy: a randomized controlled trial. Allergy. 2004;59:883-887.
33. Kuling M, Kettke U, Wahn V, et al. Development of seasonal allergic rhinitis during the first 7 years of life. J Allergy Clin Immunol. 2000;106:832-839.
34. Mosges R, Klimek L. Today's allergic rhinitis patients are different: new factors that may play a role. Allergy. 2007;62:969-975.
35. Passalacqua G. Specific immunotherapy: beyond the clinical scores. Ann Allergy Asthma Immunol. 2011;107:401-406.
36. Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitization in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year follow-up study. Clin Exp Allergy. 2001;31:1392-1397.
37. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102:558-562.
38. Hatzler L, Panetta V, Lau S, et al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol. 2012;130:894-901.
39. Matricardi PM. Molecular profile clustering of IgE responses and potential implications for specific immunotherapy. Curr Opin Allergy Clin Immunol. 2013;13:438-445.
40. Matricardi PM. Allergen-specific immunoprophylaxis: toward secondary prevention of allergic rhinitis? Pediatr Allergy Immunol. 2014;25:15-18.
41. Holt PG. Immunoprophylaxis of atopy: light at the end of the tunnel? Immunol Today. 1994;15:484-9. 13.
42. Holt PG, Sly PD, Sampson HA, et al. Prophylactic use of sublingual allergen immunotherapy in high-risk children: a pilot study. J Allergy Clin Immunol. 2013;132:991-993.
43. Nieto A, Wahn U, Bufe A. Allergy and asthma prevention 2014. Pediatr Allergy Immunol. 2014;25:516-533.
44. Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. Curr Opin Allergy Clin Immunol. 2008;8:585-589.
45. Canonica GW, Passalacqua G. Diseasemodifying effect and economic implications of Sublingual immunotherapy. J Allergy Clin Immunol. 2011;127:44-45.
46. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127:S1-S55.
47. Calderon MA, Gerth Van Wijk R, Eichler I, et al Perspectives on allergenspecific immunotherapy in childhood: an EAACI position paper. Pediatr Allergy Immunol. 2012;23:300-306.
48. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3-to 7 years. Ann Allergy Asthma Immunol. 2005;95:254-258.
49. Kim JM, Lin SY, Suarez-Cuervo C, et al. Allergen specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics. 2013;131:1155-1167.
50. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010;126:969.
51. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2011;11:586-593.
52. Hsu NM, Reisacher WR. A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. Int Forum Allergy Rhinol. 2012;2:280.
53. Pajno GB, Caminiti L, Crisafulli G, et al. Adherence to sublingual immunotherapy in preschool children. Pediatr Allergy Immunol. 2012;23:688-689.
54. Cox LS, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117:1021-1035.
55. Larenas-Linnemann D, Blaiss M, Van Bever HP, et al. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Ann Allergy Asthma Immunol. 2013;110:402-415.
56. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy. 2009;64:963-964.
57. Eifan AO, Keles S, Bahceciler NN, et al. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy. 2007;62:567-568.
58. Antico A, Fante R. Esophageal hypereosinophilia induced by grass sublingual immunotherapy. J Allergy Clin Immunol. 2014;133(5):1482-1484.
59. Cox L, Larenas-Linnemann D, Lockey RF, et al. Speaking the same language: The World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol. 2010;125:569-574, 574, e561-574, e567.
60. Passalacqua G, Baena-Cagnani CE, Bousquet J, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol. 2013;132(1):93-98.
61. Pitsios C, Demoly P, Bilò MB, et al Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy. 2015. [Epub ahead of print]. doi:10.1111.
62. Marshall GD Jr. AIDS, HIV-positive patients, and allergies. Allergy Asthma Proc. 1999;20:301-304.
63. Randhawa IS, Junaid I, Klaustermeyer WB. Allergen immunotherapy in a patient with human immunodeficiency virus: effect on T-cell activation and viral replication. Ann Allergy Asthma Immunol. 2007;98:495-497.
64. Steiner UC, Furrer H, Helbling A. Specific immunotherapy in a pollenallergic patient with human immunodeficiency virus infection. World Allergy Organ J. 2009;2:57-58.
65. Linneberg A, Jacobsen RK, Jespersen L, et al. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol. 2012;129:413-419.
66. Scadding G, Durham SR. Mechanisms of sublingual immunotherapy. Immunol. Allergy Clin North Am. 2011;31:191-209.
67. Pajno GB, Nadeau KC, Passalacqua G, et al. The evolution of allergen and non-specific immunotherapy: past achievements, current applications and future outlook. Expert Rev Clin Immunol. 2015;11:141-154.
68. Le UH, Burks AW. Oral and sublingual immunotherapy for food allergy. World Allergy Organ J. 2014;7(1):35.
69. Chin SJ, Vickery BP, Kulis MD, et al. Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. J Allergy Clin Immunol. 2013;132:476-478, e472.
70. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129:448-455, 455, e441-445.
71. Bae JM, Chi YY, Park CO, et al. Efficacy of allergen specific immunotherapy for atopic dermatitis: a systemic review and meta-analysis of randomized controlled trial. J Allergy Clin Immunol. 2013;132:110-117.
72. Compalati E, Rogkakou A, Passalacqua G, et al. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review. Curr Opin Allergy Clin Immunol. 2012;12:427-433.